RxDoctor Payments DataLook up a doctor →

Antonio Mendes, MD

Internal Medicine · Roslindale, MANPI 1659347961

Payments from drug & device makers

$3,132,564in general payments, 2019–2025

Across 967 payments — averaging $3239.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$712K
  • Biohaven Pharmaceuticals, Inc.$712K
  • Biohaven Pharmaceutical Holding Company Ltd.$456K
  • AbbVie$319K
  • AstraZeneca$298K
  • Sanofi Pasteur Inc.$185K
  • plus $451K from 39 others
$180,158in research payments, 2019–2025

Across 39 payments — averaging $4619.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$178K
  • Sanofi Pasteur Inc.$1K
  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly48$712,331
Biohaven Pharmaceuticals, Inc.49$711,982
Biohaven Pharmaceutical Holding Company Ltd.54$455,777
AbbVie(2 entities)184$319,098
AstraZeneca(2 entities)72$298,061
Sanofi Pasteur Inc.13$184,512
Ipsen Innovation189$144,381
Biogen15$114,358
Pfizer58$82,167
Axsome Therapeutics, Inc.12$45,607
GSK6$20,142
Lexicon Pharmaceuticals, Inc.5$18,353
Ultragenyx Pharmaceutical Inc.4$15,728
Amgen24$4,758
Merck15$1,397
Lilly USA, LLC32$503
Novartis24$495
Bayer9$319
Amarin Pharma, Inc.30$313
Novo Nordisk17$265
E.r. Squibb & Sons, L.L.C.11$235
Nestle Healthcare Nutrition Inc.13$235
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$170
Medtronic6$158
Mylan Specialty L.p.9$157
Johnson & Johnson6$133
Sunovion Pharmaceuticals Inc.9$126
Vanda Pharmaceuticals Inc.6$102
Teva Pharmaceuticals USA, Inc.5$101
Shield Therapeutics Inc4$90
Boehringer Ingelheim4$84
Astellas Pharma US Inc5$84
Exact Sciences3$55
Tolmar, Inc.2$42
Lundbeck LLC2$40
Phathom Pharmaceuticals, Inc.2$33
Hikma Pharmaceuticals USA2$32
Actelion Pharmaceuticals US, Inc.1$25
Bausch Health US, LLC1$24
Takeda Pharmaceuticals U.S.A., Inc.1$22
Almatica Pharma LLC1$22
Kowa Pharmaceuticals America, Inc.1$14
Endo Pharmaceuticals Inc.1$12
Esperion Therapeutics, Inc.1$12
Melinta Therapeutics, LLC1$11

How this compares

$3,132,564 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$100,235
Medicare patients
143
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Roslindale

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →